Medullary Carcinoma

This is a type of cancer that starts in the lining of glands. It can occur in different parts of the body, like the breast or the thyroid. It's a less common type of cancer.

Condition

What people with Medullary Carcinoma report

Every report comes from a Lived member, sent anonymously.

Have you had Thyroid Surgery for Medullary Carcinoma?

NameHow it went

About Medullary Carcinoma

What It Is

Medullary carcinoma is a name pathologists use for cancers whose cells grow in solid, sheet-like masses with very little of the fibrous supporting tissue most tumors contain. In practice the term mainly refers to two unrelated cancers: medullary thyroid cancer and a medullary form of breast cancer. They begin in different organs, have different causes and are treated differently, so the first thing to know about any diagnosis is which one it means. Medullary thyroid cancer (MTC) starts in the C cells of the thyroid, the butterfly-shaped gland in the front of the neck. C cells make calcitonin, a hormone involved in calcium balance, rather than the thyroid hormone produced by the rest of the gland. MTC accounts for about 3 to 4 percent of thyroid cancers. It is usually more aggressive than the common papillary and follicular types, but it often grows relatively slowly, and surgery can cure it when it is found early. Medullary breast cancer is an uncommon form of invasive breast cancer. These tumors tend to have smooth, well-defined borders and are packed with immune cells called lymphocytes. Most are triple-negative, meaning they lack the estrogen and progesterone receptors and the growth-signal protein HER2 that many breast cancer treatments target. The current World Health Organization classification no longer counts it as a separate type, so a pathology report may describe it as invasive breast carcinoma of no special type with a medullary pattern. Renal medullary carcinoma, a rare and aggressive kidney cancer seen mostly in young people with sickle cell trait, shares part of the name but is a separate disease that this page does not cover.

Causes & Risk Factors

For medullary thyroid cancer, the important distinction is whether it is inherited. About three in four cases are sporadic, meaning they arise without an inherited cause. About one in four is hereditary, caused by a change in the RET gene that is passed from parent to child. Hereditary MTC usually affects both sides of the thyroid and is often part of multiple endocrine neoplasia type 2 (MEN2), a family syndrome that can also cause pheochromocytoma (an adrenal gland tumor that releases adrenaline-like hormones) and overactive parathyroid glands. Because a RET change is shared within families, one person's diagnosis can matter for parents, siblings and children. For medullary breast cancer, no specific cause is known beyond the general risk factors for breast cancer. It tends to be diagnosed at a younger age than typical breast cancer, and it has a recognized link to inherited variants in the BRCA1 gene. Studies have found BRCA1 variants in anywhere from under 10 percent to about a third of people with medullary breast cancer, depending on the population studied. Most people with this cancer do not have an inherited variant, but the link is strong enough to make genetic testing worth discussing.

How It's Diagnosed

Medullary thyroid cancer usually first shows up as a lump in the thyroid or neck, sometimes found by chance on a scan done for another reason. A fine needle aspiration biopsy, in which a thin needle draws cells from the lump, is the usual first test. When the result points to MTC, blood levels of calcitonin and carcinoembryonic antigen (CEA), two proteins these tumors release, are measured. They are typically raised, which helps confirm the diagnosis and plan the right operation. Routine thyroid function tests such as TSH (thyroid-stimulating hormone) are usually normal, so normal thyroid blood tests do not rule MTC out. A neck ultrasound maps the thyroid and nearby lymph nodes before surgery, and when calcitonin is very high, further imaging checks whether the cancer has spread beyond the neck. Everyone diagnosed with MTC should be offered RET genetic testing, even with no family history. If an inherited change is found, the person is also checked for pheochromocytoma and parathyroid problems, and close relatives can be tested with a blood sample. Medullary breast cancer is found like other breast cancers, through a lump or an abnormal mammogram, and confirmed by biopsy. The pathologist describes the tumor's features and tests it for estrogen receptors, progesterone receptors and HER2. Those results, along with tumor size and whether lymph nodes are involved, guide treatment. Because most of these tumors are triple-negative and many are linked to BRCA1, a referral for genetic counseling is often part of the workup.

Treatment Options

For medullary thyroid cancer, surgery is the main treatment and the one that offers a cure. The usual operation is total thyroidectomy (removal of the whole thyroid) together with nearby lymph nodes, since MTC has spread to neck lymph nodes in about half of people by the time it is found. Afterward, everyone takes thyroid hormone replacement (levothyroxine) for life, at a dose that keeps TSH in the normal range. Radioactive iodine, a standard treatment for papillary and follicular thyroid cancer, does not work for MTC because C cells do not take up iodine. External radiation may be used when cancer returns in the neck. For relatives who carry an inherited RET change, removing the thyroid before cancer develops, or while it is still at a very early stage, can prevent MTC or catch it when it is most curable. This can include young children. When MTC has spread beyond what surgery can remove and is growing or causing symptoms, targeted pills called kinase inhibitors can help control it. Selpercatinib (Retevmo) blocks the RET protein directly and is approved for advanced MTC with a RET mutation in adults and children 2 and older. Vandetanib (Caprelsa) and cabozantinib (Cometriq) block several growth signals, including RET. These medicines do not cure widespread cancer, but they can often slow it or shrink it for a time. Their side effects are significant (vandetanib, for example, can disturb heart rhythm and requires regular heart monitoring), so for cancer that is growing slowly and causing no symptoms, careful monitoring may be a reasonable alternative to starting one right away. Chemotherapy is mainly used to relieve symptoms. Medullary breast cancer is treated with the same approach used for other invasive breast cancers, based on tumor size, lymph node involvement and receptor results. Surgery removes the tumor, and radiation, chemotherapy, hormone therapy and HER2-targeted drugs are added selectively. Because most of these tumors are triple-negative, chemotherapy is common, while hormone therapy and HER2-targeted drugs help only the minority of tumors that carry those receptors. The disease is rare enough that research specific to it is limited, and whether radiation adds benefit for every person remains debated.

What to Expect

With medullary thyroid cancer, the outlook depends mainly on how far the cancer had spread when it was found and whether surgery removed all of it. Across all stages combined, about 86 percent of people are alive five years after diagnosis and about 65 percent at ten years. These figures describe groups, not an individual, and people found early, especially through family genetic testing, do best. Even when the cancer is not caught early, it often progresses relatively slowly. Follow-up for MTC is lifelong. Visits include a neck examination, neck ultrasound and blood tests for calcitonin and CEA, which serve as tumor markers. After successful surgery, calcitonin should fall to an essentially undetectable level. A detectable or rising level suggests cancer remains or has returned and leads to further tests. Recurrence can happen many years after treatment, which is why monitoring continues even when results have been reassuring. Day to day, life after thyroidectomy involves a daily thyroid hormone pill and periodic TSH checks to adjust the dose. Because MTC is uncommon, care is often coordinated with an endocrinologist and a center experienced in this cancer. Medullary breast cancer often looks aggressive under the microscope, with fast-growing cells and no hormone receptors. Even so, several large studies have found survival as good as or better than for the most common type of invasive breast cancer, though not every study agrees. Age, tumor size and lymph node involvement matter more for the outlook than the label itself. Follow-up is the same as after other breast cancers. If genetic testing finds a BRCA1 variant, it opens options for extra screening and prevention for the person and their relatives.

When to Seek Help

Arrange a medical evaluation for a lump in the neck or breast that persists or grows, or for hoarseness or trouble swallowing that does not go away. If a relative has been diagnosed with MTC or carries a RET change, ask about genetic testing for yourself and your children. If you have hereditary MTC or carry a RET change, tell your care team about episodes of pounding headache, sweating, a racing heart or high blood pressure readings, which can be signs of pheochromocytoma. After treatment for either cancer, contact your care team promptly about a new lump in the neck, armpit or breast, or symptoms that are new and persistent, rather than waiting for the next scheduled visit.

Questions to Ask Your Doctor

  1. 1.Is my medullary carcinoma in the thyroid or the breast, and what do my pathology and blood test results mean for my treatment?
  2. 2.Should I have genetic testing for RET or BRCA1, and what would the results mean for my children and other relatives?
  3. 3.Has the cancer spread to lymph nodes or elsewhere, and does surgery give me a realistic chance of cure?
  4. 4.Which markers or scans will we follow, how often, and what change would lead us to consider a new treatment?
  5. 5.Does this team have experience with this rare cancer, and are there clinical trials I should consider?

Last reviewed • Oct 2026

Educational content, not medical advice.